Cantor Fitzgerald Starts Celgene (CELG) at Buy; Pipeline is Considerable
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Price: $108.24 --0%
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 10
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 10
Join SI Premium – FREE
Cantor Fitzgerald initiates coverage on Celgene (NASDAQ: CELG) with a Buy. PT $90.00.
Analyst, Mara Goldstein, said, "Celgene is at a critical juncture, with multiple catalysts in the near term that have the ability to deliver on the company's "transformational milestones" objectives that enhance growth prospects and diversify dependence from Revlimid, the flagship product for multiple myeloma."
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $80.29 yesterday.
Analyst, Mara Goldstein, said, "Celgene is at a critical juncture, with multiple catalysts in the near term that have the ability to deliver on the company's "transformational milestones" objectives that enhance growth prospects and diversify dependence from Revlimid, the flagship product for multiple myeloma."
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $80.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loop Capital Starts Instacart (CART) at Buy, 'Leading a Massive and Underpenetrated Category'
- Northcoast Research Starts Deluxe Corp (DLX) at Buy
- TD Cowen Resumes EQT Corp. (EQT) at Hold
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
